Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
Status:
Recruiting
Trial end date:
2023-04-29
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and
safety of 24 once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes
mellitus (T2DM) not well-controlled by metformin monotherapy.